Mostrando 4,961 - 4,980 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.33s Limitar resultados
  1. 4961
  2. 4962
    “…BACKGROUND: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Quality of life (QoL) is an important endpoint that affects treatment decisions. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 4963
  4. 4964
  5. 4965
  6. 4966
  7. 4967
  8. 4968
  9. 4969
  10. 4970
    por Schumann, Robert, 1810-1856
    Publicado 1938
    Partituras Libro
  11. 4971
    Publicado 1975
    Libro
  12. 4972
    por Ardoin, John
    Publicado 1995
    Libro
  13. 4973
    “…SIMPLE SUMMARY: The 21-gene Oncotype DX Breast Recurrence Score(®) assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2−) in Early Breast Cancer (EBC). The KARMA Dx study evaluated the impact of the Recurrence Score(®) results (RS) on the treatment decision for patients with EBC and high-risk clinicopathological characteristics for whom chemotherapy (CT) was considered. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 4974
  15. 4975
    “…The primary endpoints were(a) the diagnostic value of dPCR for detecting HER2 status in the blood and(b) the relevance of potential changes in the plasma HER2 level at 3 weeks from baseline for predicting treatment response. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 4976
    “…CONCLUSIONS: Palbociclib plus fulvestrant is unlikely to be cost-effective in comparison with placebo plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  17. 4977
  18. 4978
  19. 4979
    “…BACKGROUND: Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer. Preclinically, cancer cells harboring double or multiple PIK3CA mutations (mut) elicit hyperactivation of the PI3K pathway leading to enhanced sensitivity to p110α inhibitors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 4980
Herramientas de búsqueda: RSS